Pivotal phase III results of afatinib as first-line treatment in patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations

Results from LUX-Lung 3, the pivotal phase III randomized, open-label, lung cancer trial investigating the ErbB family blocker afatinib, in patients with EGFR mutations, were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (1 - 5 June 2012). LUX-Lung 3, which compares afatinib to standard platinum based chemotherapy, is the largest phase III trial in first-line EGFR mutation positive, advanced, metastatic non-small cell lung cancer (NSCLC) patients. LUX-Lung 3 is also the first study using pemetrexed/cisplatin as a comparator. Read the news article here.